Evolutionary Strategies of High-Risk Pathogens

Extensively drug-resistant (XDR) Klebsiella pneumoniae remains a significant challenge for healthcare systems globally. Specifically, the emergence of Klebsiella pneumoniae pandemic clones such as ST258 and ST307 highlights the diverse evolutionary strategies bacteria use to survive. While both lineages have achieved pandemic status, they utilize distinct genomic mechanisms to spread and resist treatment. Understanding these trajectories is vital for clinical management in regions like India, where carbapenem resistance is endemic.

Historically, ST258 first appeared in the United States around 1995. This clone primarily evolves through recombination and maintains a stable association with the blaKPC-2/3 resistance gene. For years, ST258 remained largely hospital-endemic, dominating the epidemiology of carbapenem-resistant Enterobacteriaceae. Although it maintained a strong presence for two decades, its prevalence began to decline after 2015 as newer lineages emerged.

In contrast, ST307 emerged in the Netherlands in 2008 and demonstrates remarkable plasmid-mediated adaptability. This lineage successfully carries a wide array of carbapenemases, including blaNDM, OXA, and KPC. By 2025, ST307 has achieved rapid global dissemination across all six WHO regions. Furthermore, emerging hypervirulent sublineages of ST307 in Europe and South America pose an even greater risk to patient outcomes due to their dual threat of resistance and high pathogenicity.

Clinical Impact of Klebsiella pneumoniae Pandemic Clones

Clinicians must recognize that these two strategies—recombination-driven stability versus plasmid-driven adaptability—converge into a unified global threat. Because these clones show limited susceptibility to current therapies, including last-resort agents, researchers must focus on developing new antimicrobial options. Moreover, coordinated global surveillance is essential to monitor the microevolution of these resistant strains. Notably, the rapid spread of ST307 suggests that high-risk clones can outcompete traditional hospital-bound lineages by adapting to diverse environments and hosts.

Ultimately, the parallel success of ST258 and ST307 reflects the fitness landscapes they navigate. Consequently, healthcare facilities must implement strict infection control measures and antimicrobial stewardship to mitigate the impact of these pandemic threats. Additionally, ongoing research into evolutionary dynamics will provide insights into future resistance trends.

How do ST258 and ST307 differ in their evolution?

ST258 relies on recombination-driven evolution and maintains stable resistance genes like blaKPC. In contrast, ST307 uses plasmid-mediated adaptability to acquire diverse carbapenemase genes and hypervirulence factors.

Why is ST307 considered a greater threat today?

ST307 demonstrates higher adaptability and has spread rapidly to all six WHO regions. It frequently carries multiple resistance genes, including NDM and OXA, and is developing hypervirulent sublineages.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Sarkar SN et al. Parallel evolutionary trajectories of extensively drug-resistant Klebsiella pneumoniae ST258 and ST307 pandemic clones: a systematic review. Can J Microbiol. 2026 Mar 17. doi: 10.1139/cjm-2025-0268. PMID: 41843925.

Peirano G, et al. (2020). Global epidemiology of ST307 Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy.

Wyres KL, et al. (2020). Genomic surveillance for hypervirulence and multi-drug resistance in Klebsiella pneumoniae. Lancet Infectious Diseases.